435 related articles for article (PubMed ID: 26593208)
1. Oncogenic miR-9 is a target of erlotinib in NSCLCs.
Chen X; Zhu L; Ma Z; Sun G; Luo X; Li M; Zhai S; Li P; Wang X
Sci Rep; 2015 Nov; 5():17031. PubMed ID: 26593208
[TBL] [Abstract][Full Text] [Related]
2. MiR-183 promotes growth of non-small cell lung cancer cells through FoxO1 inhibition.
Zhang L; Quan H; Wang S; Li X; Che X
Tumour Biol; 2015 Sep; 36(10):8121-6. PubMed ID: 25983004
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of miR-641 contributes to erlotinib resistance in non-small-cell lung cancer cells by targeting NF1.
Chen J; Cui JD; Guo XT; Cao X; Li Q
Cancer Med; 2018 Apr; 7(4):1394-1403. PubMed ID: 29493886
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.
Liao J; Lin J; Lin D; Zou C; Kurata J; Lin R; He Z; Su Y
Sci Rep; 2017 Apr; 7(1):781. PubMed ID: 28396596
[TBL] [Abstract][Full Text] [Related]
5. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
6. FOXP4 modulates tumor growth and independently associates with miR-138 in non-small cell lung cancer cells.
Yang T; Li H; Thakur A; Chen T; Xue J; Li D; Chen M
Tumour Biol; 2015 Sep; 36(10):8185-91. PubMed ID: 25994569
[TBL] [Abstract][Full Text] [Related]
7. Critical role of miR-155/FoxO1/ROS axis in the regulation of non-small cell lung carcinomas.
Hou L; Chen J; Zheng Y; Wu C
Tumour Biol; 2016 Apr; 37(4):5185-92. PubMed ID: 26548866
[TBL] [Abstract][Full Text] [Related]
8. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
[TBL] [Abstract][Full Text] [Related]
9. Posttranslational modifications of FOXO1 regulate epidermal growth factor receptor tyrosine kinase inhibitor resistance for non-small cell lung cancer cells.
Xu ZH; Shun WW; Hang JB; Gao BL; Hu JA
Tumour Biol; 2015 Jul; 36(7):5485-95. PubMed ID: 26036758
[TBL] [Abstract][Full Text] [Related]
10. Role of miR-497 in VEGF-A-mediated cancer cell growth and invasion in non-small cell lung cancer.
Gu A; Lu J; Wang W; Shi C; Han B; Yao M
Int J Biochem Cell Biol; 2016 Jan; 70():118-25. PubMed ID: 26485685
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of miR-506-3p Facilitates EGFR-TKI Resistance through Induction of Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines.
Haque I; Kawsar HI; Motes H; Sharma M; Banerjee S; Banerjee SK; Godwin AK; Huang CH
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291316
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.
Ahmad A; Maitah MY; Ginnebaugh KR; Li Y; Bao B; Gadgeel SM; Sarkar FH
J Hematol Oncol; 2013 Oct; 6(1):77. PubMed ID: 24199791
[TBL] [Abstract][Full Text] [Related]
13. miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway.
Han J; Zhao F; Zhang J; Zhu H; Ma H; Li X; Peng L; Sun J; Chen Z
Int J Oncol; 2016 May; 48(5):1855-67. PubMed ID: 26936292
[TBL] [Abstract][Full Text] [Related]
14. miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor.
Zhao FY; Han J; Chen XW; Wang J; Wang XD; Sun JG; Chen ZT
Int J Mol Med; 2016 Jul; 38(1):183-91. PubMed ID: 27177336
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway.
Han Z; Zhou X; Li S; Qin Y; Chen Y; Liu H
Oncol Rep; 2017 Nov; 38(5):3064-3070. PubMed ID: 28901474
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-96 promotes the proliferation of colorectal cancer cells and targets tumor protein p53 inducible nuclear protein 1, forkhead box protein O1 (FOXO1) and FOXO3a.
Gao F; Wang W
Mol Med Rep; 2015 Feb; 11(2):1200-6. PubMed ID: 25369914
[TBL] [Abstract][Full Text] [Related]
17. miR-17-5p down-regulation contributes to erlotinib resistance in non-small cell lung cancer cells.
Zhang W; Lin J; Wang P; Sun J
J Drug Target; 2017 Feb; 25(2):125-131. PubMed ID: 27633093
[TBL] [Abstract][Full Text] [Related]
18. NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers.
Wang X; Yin H; Zhang H; Hu J; Lu H; Li C; Cao M; Yan S; Cai L
Cell Death Dis; 2018 Apr; 9(4):418. PubMed ID: 29549343
[TBL] [Abstract][Full Text] [Related]
19. Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib.
Amri J; Molaee N; Baazm M; Karami H
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2781-2787. PubMed ID: 31554377
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/
Zhang H; Chen F; He Y; Yi L; Ge C; Shi X; Tang C; Wang D; Wu Y; Nian W
Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28507201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]